Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
10x Genomics, Inc. (TXG)
|
Add to portfolio |
|
|
|
| Price: |
$145.79
| | Metrics |
| OS: |
116.2
|
M
| |
|
|
| Market cap: |
$16.9
|
B
| |
|
|
|
Net cash:
|
$391
|
M
| |
$3.37
|
per share
|
|
EV:
|
$16.5
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($112)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 490.5 | 298.8 | 245.9 | 146.3 | 71.1 |
| Revenue growth | 64.1% | 21.5% | 68.1% | 105.8% | |
| Cost of goods sold | 74.1 | 58.5 | 61.0 | 28.7 | 10.6 |
| Gross profit | 416.4 | 240.4 | 184.9 | 117.7 | 60.5 |
| Gross margin | 84.9% | 80.4% | 75.2% | 80.4% | 85.1% |
| Selling, general and administrative | 257.6 | 202.3 | 130.8 | 87.9 | 46.7 |
| Research and development | 211.8 | 123.4 | 83.1 | 47.5 | 32.2 |
| EBIT | -52.3 | -86.6 | -30.6 | -48.4 | -18.4 |
| EBIT margin | -10.7% | -29.0% | -12.4% | -33.1% | -25.8% |
| Pre-tax income | -53.7 | -534.5 | -31.0 | -112.4 | -18.7 |
| Income taxes | 4.5 | 8.3 | 0.2 | 0.1 | 0.0 |
| Net income | -58.2 | -542.7 | -31.3 | -112.5 | -18.8 |
| Net margin | -11.9% | -181.6% | -12.7% | -76.9% | -26.4% |
| |
| Diluted EPS | ($0.53) | ($5.37) | ($0.80) | ($8.40) | ($1.62) |
| Shares outstanding (diluted) | 110.3 | 101.2 | 39.1 | 13.4 | 11.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|